Prof. Yanay Ofran’s amazing story about the pursuit of an antibody that will save the world from disease Shlomit Lan and Gali Weinreb Professor Yanay Ofran, founder and CEO of Biolojic Design, a company that develops smart antibodies designed to treat a variety of diseases, is frustrated. “Humanity invests $300 billion each year in drug development, and what do we get? At most, we get a few dozen medications a year, most of which don’t solve the problems, and give an additional three weeks of life on average to patients with pancreatic cancer, or manage to inject a medication that to date was given via infusion. Those are the breakthroughs,” he says despairingly.BOSTON and TEL AVIV, Israel, March 30, 2021 /PRNewswire/ — Aulos Bioscience, a biotechnology company developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors, announced today the appointment of Mace Rothenberg, M.D., to the company’s board of directors.
Read more here.